Literature DB >> 16173043

N-cadherin switching occurs in high Gleason grade prostate cancer.

Meena Jaggi1, Tanya Nazemi, Neil A Abrahams, John J Baker, Anton Galich, Lynette M Smith, K C Balaji.   

Abstract

BACKGROUND: The inappropriate expression of non-epithelial N-(neural) cadherin by epithelial cells, called cadherin switching, has been suggested to play a role in prostate cancer (PC) progression. We explored the role of N-cadherin as a biomarker in PC by correlating the expression with clinical parameters.
METHODS: Two pathologists blinded to patients' history independently reviewed and scored the intensity and extent of staining of N-cadherin expression in 44 randomly selected radical prostatectomy specimens. The expression was correlated with total Gleason grade, individual Gleason patterns, tumor stage, and preoperative serum prostate specific antigen (PSA) levels and P-values < 0.05 were considered statistically significant.
RESULTS: Of the 44 PC specimens, 14 (32%), 23 (52%), 7 (16%) consisted of Gleason grade 5-6, 7, and 8-10, respectively and 20/44 (45%) demonstrated N-cadherin expression. N-cadherin was expressed in 1/14 (7%) of Gleason 5-6 compared to 15/23 (65%) of Gleason grade 7, and 4/7 (57%) of Gleason grade 8-10, demonstrating a significant correlation between N-cadherin switching and higher Gleason grade (P = 0.001). While only about a third of primary or secondary Gleason pattern 3 demonstrated N-cadherin expression, a majority of Gleason patterns of > or = 4 expressed N-cadherin (P > 0.05), further suggesting that N-cadherin switching occurs with higher Gleason pattern. However, N-cadherin expression did not significantly correlate with preoperative serum PSA levels or tumor stage in our study cohort.
CONCLUSIONS: We have demonstrated for the first time that N-cadherin switching occurs in higher grade PC and correlates significantly with increasing Gleason patterns. N-cadherin may be as a useful biomarker of aggressive PC. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16173043     DOI: 10.1002/pros.20334

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  31 in total

1.  MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms.

Authors:  Y-N Liu; J J Yin; W Abou-Kheir; P G Hynes; O M Casey; L Fang; M Yi; R M Stephens; V Seng; H Sheppard-Tillman; P Martin; K Kelly
Journal:  Oncogene       Date:  2012-02-27       Impact factor: 9.867

2.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Susan Chilton-Macneill; Jane Bayani; Shamini Selvarajah; Andrew J Evans; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

3.  Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression.

Authors:  Bilal Bin Hafeez; Aditya Ganju; Mohammed Sikander; Vivek K Kashyap; Zubair Bin Hafeez; Neeraj Chauhan; Shabnam Malik; Andrew E Massey; Manish K Tripathi; Fathi T Halaweish; Nadeem Zafar; Man M Singh; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

4.  Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.

Authors:  Hiroshi Tanaka; Evelyn Kono; Chau P Tran; Hideyo Miyazaki; Joyce Yamashiro; Tatsuya Shimomura; Ladan Fazli; Robert Wada; Jiaoti Huang; Robert L Vessella; Jaibin An; Steven Horvath; Martin Gleave; Matthew B Rettig; Zev A Wainberg; Robert E Reiter
Journal:  Nat Med       Date:  2010-11-07       Impact factor: 53.440

5.  Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition.

Authors:  Yen-Nien Liu; Wassim Abou-Kheir; Juan Juan Yin; Lei Fang; Paul Hynes; Orla Casey; Dong Hu; Yong Wan; Victoria Seng; Heather Sheppard-Tillman; Philip Martin; Kathleen Kelly
Journal:  Mol Cell Biol       Date:  2011-12-27       Impact factor: 4.272

6.  Hyaluronan suppresses prostate tumor cell proliferation through diminished expression of N-cadherin and aberrant growth factor receptor signaling.

Authors:  Alamelu G Bharadwaj; Nathaniel P Goodrich; Caitlin O McAtee; Katie Haferbier; Gregory G Oakley; James K Wahl; Melanie A Simpson
Journal:  Exp Cell Res       Date:  2011-02-17       Impact factor: 3.905

7.  Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.

Authors:  Tanya Stoyanova; Mireille Riedinger; Shu Lin; Claire M Faltermeier; Bryan A Smith; Kelvin X Zhang; Catherine C Going; Andrew S Goldstein; John K Lee; Justin M Drake; Meghan A Rice; En-Chi Hsu; Behdokht Nowroozizadeh; Brandon Castor; Sandra Y Orellana; Steven M Blum; Donghui Cheng; Kenneth J Pienta; Robert E Reiter; Sharon J Pitteri; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-30       Impact factor: 11.205

8.  Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis.

Authors:  Daxing Xie; Crystal Gore; Jun Liu; Rey-Chen Pong; Ralph Mason; Guiyang Hao; Michael Long; Wareef Kabbani; Luyang Yu; Haifeng Zhang; Hong Chen; Xiankai Sun; David A Boothman; Wang Min; Jer-Tsong Hsieh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-13       Impact factor: 11.205

9.  N-cadherin knock-down decreases invasiveness of esophageal squamous cell carcinoma in vitro.

Authors:  Ke Li; Wei He; Na Lin; Xin Wang; Qing-Xia Fan
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

Review 10.  Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena.

Authors:  Richard T Bryan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-02-05       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.